Stanley Druckenmiller Eli Lilly & CO Transaction History

Duquesne Family Office LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$592.2 - $792.28 $202 Million - $270 Million	-340,886 Reduced 84.68%	61,664 $48 Million
Q4 2023 Feb 14, 2024	SELL	$525.19 - $619.13 $27.1 Million - $31.9 Million	-51,565 Reduced 11.36%	402,550 $235 Million
Q3 2023 Nov 14, 2023	SELL	$434.7 - $599.3 $35.8 Million - $49.3 Million	-82,330 Reduced 15.35%	454,115 $244 Million
Q2 2023 Aug 14, 2023	SELL	$350.74 - $468.98 $24.5 Million - $32.7 Million	-69,765 Reduced 11.51%	536,445 $252 Million
Q1 2023 May 15, 2023	SELL	$310.63 - $364.82 $40.9 Million - $48 Million	-131,515 Reduced 17.83%	606,210 $208 Million
Q4 2022 Feb 14, 2023	BUY	$321.55 - $374.67 $81.3 Million - $94.7 Million	252,830 Added 52.14%	737,725 $270 Million
Q3 2022 Nov 14, 2022	BUY	$296.48 - $337.87 $55.7 Million - $63.4 Million	187,745 Added 63.18%	484,895 $157 Million
Q2 2022 Aug 15, 2022	BUY	$278.73 - $327.27 $82.8 Million - $97.2 Million	297,150 New	297,150 $96.3 Million

4,011

751M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $756B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Duquesne Family Office LLC, based on Form 13F filings with the SEC.

Stay updated on Duquesne Family Office LLC and Stanley Druckenmiller with notifications on news.